Original Source(s)
Related Content
FDA Expands CAPVAXIVE Pediatric Use
Phase 3 data showed noninferior immune responses vs pneumococcal 23-valent polysaccharide vaccine in pediatric patients at increased risk.
June 18, 2026
-
2 min
Weekly HIV Therapy Meets Primary Endpoint
Patients who switched from daily antiretroviral therapy maintained virologic suppression in two phase 3 trials.
July 23, 2026
-
3 min
Self-Sampling Shows Test Agreement
The study authors frame the device as a potential way to simplify screening, while emphasizing that larger validation studies are still needed.
July 8, 2026
-
5 min